21:58 , May 24, 2019 |  BioCentury  |  Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
00:08 , Jan 23, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Leukemia; cancer Cell culture and mouse studies identified an MDM2 protein degrader that could help treat leukemia and other cancers. Chemical synthesis and testing of analogs of an MDM2 inhibitor tool compound linked to...
20:40 , Jan 18, 2019 |  BC Week In Review  |  Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets. MD Anderson's...
22:44 , Jan 7, 2019 |  BC Extra  |  Politics & Policy

Bipartisan bill to streamline U.S. response to foreign theft of IP may hasten clarity on biotech impact

As the biopharma industry awaits guidance from the government on the scope and potential impact of proposed technology export controls, a new congressional bill could help speed the process. Members of the Senate Select Committee...
00:38 , Aug 9, 2018 |  BC Innovations  |  Translation in Brief

Identifying the ubiquitinators

A team at University of Dundee and Newcastle University has developed a mass spectrometry-based screening platform to identify ubiquitin ligases and compounds that modulate them. The approach uses the uptake of ubiquitin by enzymes rather...
23:50 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) In vitro , cell culture and mouse studies identified a piperazine-based dual MDM2/HDAC6 inhibitor that could help treat NSCLC. Chemical synthesis and in vitro testing of conjugates consisting of...
20:12 , Aug 1, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cell-free assays; high throughput screening A high throughput, mass spectrometry-based screening assay could identify E3 ligase inhibitors and interactive pairs of E2/E3 ubiquitination enzymes as potential drug targets. For the latter, the method involves...
19:22 , Jun 20, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy MDM2-mediated inhibition of p53 could enhance the efficiency of gene insertions using CRISPR-Cas9. The modified CRISPR protocol includes treating cell culture with the p53 inhibitor MDM2, followed by administration of ribonucleoprotein complexes...
16:15 , May 4, 2018 |  BC Week In Review  |  Financial News

Unity prices $85M IPO

Unity Biotechnology Inc. (NASDAQ:UBX) raised $85 million late May 2 through the sale of 5 million shares at $17 in an IPO underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. The price was at...
23:58 , May 2, 2018 |  BC Extra  |  Financial News

Unity prices $85M IPO

Unity Biotechnology Inc. (NASDAQ:UBX) raised $85 million late Wednesday through the sale of 5 million shares at $17 in an IPO underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. The price was at the...